bioRxivCancer Biology
Anti-cancer potential of cannabis terpenes in a taxol-resistant model of breast cancer
Abstract
Chemotherapeutic resistance can limit breast cancer outcomes; therefore, the exploration of novel therapeutic options is warranted. Isolated compounds found in cannabis have previously been shown to exhibit anti-cancer effects, but little is known about their effects in resistant breast cancer. Our study aims to evaluate the effects of terpenes found in cannabis in in vitro chemotherapy-resistant model of breast cancer. We aimed to identify whether five terpenes found in cannabis produced anti-cancer effects, and if their effects were improved upon co-treatment with cannabinoids and flavonoids also found in cannabis. Nerolidol and {beta}-caryophyllene produced the greatest cytotoxic effects, activated the apoptotic cascade and reduced cellular invasion. Combinations with the flavonoid kaempferol potentiated the cytotoxic effects of ocimene, terpinolene, and {beta}-myrcene. Combinations of nerolidol and {Delta}9-tetrahydrocannabinol or cannabidiol produced variable responses ranging from antagonism and additivity to synergy, depending on concentrations used. Our results indicate that cannabis terpenes, alone or combined with cannabinoids and flavonoids, produced anti-cancer effects in chemotherapy-resistant breast cancer cell lines. This study is a first step in the identification of compounds that could have therapeutic potential in the treatment of resistant breast cancer.
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Anti-cancer properties of cannabidiol and Δ9-tetrahydrocannabinol and potential synergistic effects with gemcitabine, cisplatin and other cannabinoids in bladder cancer
A. M. Tomko, E. G. Whynot, D. J. Dupre·bioRxiv·Mar 25, 2021
- Wnt/β-catenin inhibition disrupts drug-tolerance in isogenic carboplatin-resistant models of Triple-Negative Breast Cancer.
W. A. Abreu de Oliveira, S. Moens, … F. Lluis·bioRxiv·May 21, 2021
- Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer
O. Yedier-Bayram, A. Cingoz, … T. Bagci-Onder·bioRxiv·Apr 16, 2024
- Propofol overcome Tamoxifen resistance in breast cancer by modulating tumorogenesis, immune response and metabolism
- Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalence
P. E. Petrella, J. W. Chen, … B. D. Cosgrove·bioRxiv·Apr 28, 2024
- Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer
Damilola Oluwalana, Kelli L. Adeleye, … Wěi Li·Cancer LettersPeer-reviewed·May 23, 2024